Wolf Haldenstein Announces Securities Class Action Lawsuit Against Neumora Therapeutics, Inc.

Lead Plaintiff Deadline is April 7, 2025

NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) —

Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”) announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of purchasers of Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) common stock pursuant and/or traceable to Neumora’s registration statement issued in connection with Neumora’s initial public offering (“IPO”) held on September 15, 2023. In its IPO, Neumora sold 14.7 million shares at $17.00 per share.

The lawsuit alleges that Neumora made false and misleading statements and failed to disclose material adverse facts about the company’s business, operations, and prospects. As a result of these alleged misrepresentations, Neumora’s stock price was artificially inflated during the IPO, causing investors to suffer damages.

Investors who purchased Neumora stock during the IPO and suffered losses are encouraged to contact Wolf Haldenstein before the lead plaintiff deadline on April 7, 2025.

If you believe you are a victim of securities fraud committed by Neumora Therapeutics, Inc., please CLICK HERE to provide your contact information and join the case.

How Will This Lawsuit Affect Me?

If you purchased Neumora Therapeutics, Inc. common stock during the IPO held on September 15, 2023, you may be eligible to participate in the securities class action lawsuit. By joining the lawsuit as a plaintiff, you may be able to recover some or all of your losses incurred as a result of the alleged securities fraud committed by Neumora.

How Will This Lawsuit Affect the World?

The outcome of this securities class action lawsuit against Neumora Therapeutics, Inc. may have broader implications for the financial markets and investor confidence. If Neumora is found liable for securities fraud, it could lead to increased scrutiny and regulation of companies seeking to go public through initial public offerings. Investors and regulators alike will be watching the proceedings closely to see how the case unfolds.

Conclusion

Wolf Haldenstein Adler Freeman & Herz LLP’s announcement of a securities class action lawsuit against Neumora Therapeutics, Inc. underscores the importance of transparency and accountability in the financial markets. Investors who believe they were misled by Neumora during its IPO are encouraged to seek legal recourse before the lead plaintiff deadline on April 7, 2025.